Targeted Therapy
Approved for: NSCLC
Biomarker: ALK

Alectinib (Alecensa) is a FDA-approved Targeted Therapy for Non-small cell lung cancer (NSCLC) that is ALK positive and has metastasized (spread to other parts of the body).

.

Related Research News

Pre- and Post-surgical Immunotherapy-based Treatment Significantly Improved Lung Cancer Outcomes

Pre- and Post-surgical Immunotherapy-based Treatment Significantly Improved Lung Cancer Outcomes

Long-term study reveals ‘ever-changing’ nature of lung cancer

Long-term study reveals ‘ever-changing’ nature of lung cancer

Lung Cancer Trial Has Broader Eligibility Criteria, Overcomes Barriers

Lung Cancer Trial Has Broader Eligibility Criteria, Overcomes Barriers